Global pharma giant AstraZeneca on Saturday announced a fresh investment of ₹176 crore in India to expand its Global Innovation & Technology Centre (GITC) in Chennai. This marks the company’s third investment in India within the last two years, reinforcing its commitment to healthcare innovation in the country.
According to the company, the expansion will further strengthen the GITC’s role as a global leader in healthcare technology and innovation.
"This new investment reflects our ongoing mission to improve patient lives by embedding cutting-edge technologies into every aspect of our work. Chennai continues to evolve as a vital innovation hub, and our continued growth here demonstrates the state's boundless potential," AstraZeneca India Pvt Ltd Managing Director Siva Padmanabhan said.
The investment will enhance AstraZeneca’s technology and innovation teams, covering areas such as artificial intelligence, data analytics, machine learning, data science, and supply chain analytics. These capabilities aim to accelerate next-generation medicines, enable data-driven solutions, and support future-ready healthcare ecosystems.
Quoting Tamil Nadu Chief Minister MK Stalin, the statement added: "This additional investment in Chennai is a testament to the state's reputation as a centre of excellence for global innovation." He further said the move would generate skilled opportunities, foster knowledge exchange, and reinforce Tamil Nadu’s position as a destination for advanced industries.
Beyond its innovation focus, AstraZeneca has a diverse presence in India through its specialist disease portfolio in oncology, cardiovascular, respiratory, and rare diseases. The company also operates strong hubs in technology, global business services, and R&D, with over 5,000 employees across the country.